Itepekimab for Sinusitis (CEREN1 Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you've used certain nasal sprays or systemic corticosteroids recently. It's best to discuss your specific medications with the study team.
Itepekimab, a drug that targets a protein called interleukin-33, has shown promise in reducing inflammation in asthma patients, which suggests it might help with sinusitis too, as both conditions involve inflammation. However, direct evidence for its effectiveness in sinusitis is not available yet.
12345Itepekimab has been tested in healthy adults and patients with asthma, and it was well-tolerated with no significant safety concerns reported in these studies.
13678Itepekimab is unique because it is a monoclonal antibody that targets interleukin-33, a protein involved in inflammation, which is different from other treatments like omalizumab that target IgE. This approach may offer a new way to reduce inflammation in sinusitis.
12359Eligibility Criteria
Adults with chronic rhinosinusitis and nasal polyps who haven't found relief with standard treatments can join. They must be willing to add the trial medication to their usual nasal sprays for over a year, including follow-ups.Inclusion Criteria
Exclusion Criteria